title: Tissue factor pathway inhibitor production by human mesangial cells in culture.
abstract: Fibrin formation within the glomeruli has been observed in various forms of human and experimental glomerulonephritis and it may play an important role in progressive glomerular injury. Furthermore it has been hypothesized that glomerular fibrin deposition may occur through activation of either the intrinsic or extrinsic coagulation pathway. It has been demonstrated that a procoagulant activity (PCA) which is compatible with tissue factor is present in the glomeruli and becomes increased in human proliferative glomerulonephritis and in animal models of nephritis. Tissue factor pathway inhibitor (TFPI) regulates the extrinsic pathway of blood coagulation through its ability to inhibit tissue factor activity. TFPI is present in plasma and in platelets, and it is now thought to be produced mainly by endothelial cells. We examined whether human mesangial cells (HMC) could produce TFPI and attempted to clarify regulatory factors which affect TFPI production. Cultured HMC were used and TFPI in the cell supernatants was measured by ELISA using a specific antibody. Cultured HMC showed the production of TFPI. Immunoblot analysis revealed 40 kD protein of TFPI. The concentration of TFPI was significantly increased following the incubation with thrombin and heparin, including low molecular weight heparin, in a dose- and time-dependent manner. However, fetal calf serum, phorbol myristate acetate, lipopolysaccharide, IL-1 beta and tissue factor did not stimulate TFPI synthesis. Our data show that cultured HMC have the ability to produce TFPI which inhibits fibrin formation. It is possible that thrombin-induced enhancement of TFPI synthesis may be caused by the autoregulatory system of blood coagulation and that with heparin it may represent another anticoagulatory effect of heparin.
authors.affiliation: Second Department of Internal Medicine, Hirosaki University School of Medicine, Japan.
authors.forename: H
authors.initials: H
authors.lastname: Yamabe
authors.forename: H
authors.initials: H
authors.lastname: Osawa
authors.forename: H
authors.initials: H
authors.lastname: Inuma
authors.forename: M
authors.initials: M
authors.lastname: Kaizuka
authors.forename: N
authors.initials: N
authors.lastname: Tamura
authors.forename: S
authors.initials: S
authors.lastname: Tsunoda
authors.forename: Y
authors.initials: Y
authors.lastname: Fujita
authors.forename: K
authors.initials: K
authors.lastname: Shirato
authors.forename: K
authors.initials: K
authors.lastname: Onodera
mesh_terms: D000925:Anticoagulants / Q000378:metabolism*; D002478:Cells, Cultured; D005920:Glomerular Mesangium / Q000166:cytology / Q000378:metabolism*; D006801:Humans; D015151:Immunoblotting; D008074:Lipoproteins / Q000096:biosynthesis*; D013268:Stimulation, Chemical
chemical_list: D000925:Anticoagulants; D008074:Lipoproteins; C051928:lipoprotein-associated coagulation inhibitor